Welichem Announces Filing of Phase II Multi-centre Clinical Trial Application
BURNABY, BC,
"We are very encouraged by the data on this non-steroidal, anti-inflammatory drug candidate," said
As it builds on the successfully completed clinical trials and safety studies of WBI-1001 Welichem's plans for the international phase II/III clinical program are now progressing well.
About WBI-1001
WBI-1001 is a non-steroidal, anti-inflammatory drug candidate that has been shown in prior clinical trials to be effective and to have good safety profile. WBI-1001 is a novel, patented drug candidate that is being developed by Welichem as a new treatment for AD, psoriasis and related diseases.
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of inflammatory diseases and cancer.
ON BEHALF OF THE BOARD Tan Xiangdong, Chairman The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
This press release contains forward-looking statements that include our belief as to the potential of our products, such as "results of our toxicology studies support additional, longer term clinical trials of WBI-1001", "the clinical trial application is a significant step forward in our drug development program", "Welichem plans to initiate the clinical studies in
%SEDAR: 00021386E
For further information: Genhui Chen, CEO, Tel.: (604) 432-1703, Email: [email protected]
Share this article